Cytokinetics, Incorporated (CYTK)

NASDAQ: CYTK · Real-Time Price · USD
60.17
-0.47 (-0.78%)
At close: Oct 7, 2025, 4:00 PM EDT
60.00
-0.17 (-0.28%)
After-hours: Oct 7, 2025, 5:23 PM EDT
-0.78%
Market Cap7.20B
Revenue (ttm)85.74M
Net Income (ttm)-606.31M
Shares Out 119.66M
EPS (ttm)-5.12
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,784,852
Open60.56
Previous Close60.64
Day's Range58.74 - 61.19
52-Week Range29.31 - 61.19
Beta0.68
AnalystsBuy
Price Target76.73 (+27.52%)
Earnings DateNov 5, 2025

About CYTK

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle tropo... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 29, 2004
Employees 498
Stock Exchange NASDAQ
Ticker Symbol CYTK
Full Company Profile

Financial Performance

In 2024, Cytokinetics's revenue was $18.47 million, an increase of 145.34% compared to the previous year's $7.53 million. Losses were -$589.53 million, 12.0% more than in 2023.

Financial Statements

Analyst Summary

According to 16 analysts, the average rating for CYTK stock is "Buy." The 12-month stock price target is $76.73, which is an increase of 27.52% from the latest price.

Price Target
$76.73
(27.52% upside)
Analyst Consensus: Buy
Stock Forecasts

News

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm

LOS ANGELES , Oct. 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cytokinetics, Incorpo...

10 hours ago - PRNewsWire

CYTK INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options

1 day ago - GlobeNewsWire

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm

LOS ANGELES , Sept. 30, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cytokinetics, Incor...

7 days ago - PRNewsWire

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options

7 days ago - GlobeNewsWire

Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds securities class action lawsuit has been filed in the United States District Court for the Northern Distr...

8 days ago - GlobeNewsWire

Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025

Additional Data from MAPLE-HCM Show Aficamten Significantly Improves Measures of Maximal and Submaximal Exercise Capacity and Recovery Compared to Metoprolol

8 days ago - GlobeNewsWire

Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds securities class action lawsuit has been filed in the United States District Court for the Northern Distr...

12 days ago - GlobeNewsWire

Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program

Program to Provide Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases

13 days ago - GlobeNewsWire

Cytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

SOUTH SAN FRANCISCO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company's management team are scheduled to present a corpo...

14 days ago - GlobeNewsWire

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options If you purchased or acq...

18 days ago - PRNewsWire

Cytokinetics, Inc. Investigated by the Portnoy Lawfirm

LOS ANGELES, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cytokinetics, Inc., (“Cytokinetics” or the "Company") (NASDAQ: CYTK) investors of a class action on behalf of investors tha...

19 days ago - GlobeNewsWire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2025 it granted stock options to purchase an aggregate o...

19 days ago - GlobeNewsWire

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Cytokinetics, Incorporated (CYTK)

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of ...

19 days ago - GlobeNewsWire

Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025

Long-Term Data from FOREST-HCM in Non-Obstructive HCM and Results from Prespecified Analysis of MAPLE-HCM to be Presented in Late-Breaking Clinical Research Session

19 days ago - GlobeNewsWire

Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes

SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate princ...

20 days ago - GlobeNewsWire

Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes

SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market conditions and othe...

21 days ago - GlobeNewsWire

Cytokinetics, Incorporated (CYTK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Cytokinetics, Incorporated (NASDAQ:CYTK) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 11:30 AM EDT Company Participants Fady Malik - Executive Vice President of Research ...

4 weeks ago - Seeking Alpha

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.

Other symbols: ARGXBBHBMRNIBBXBI
4 weeks ago - CNBC Television

Cytokinetics, Incorporated (CYTK) Presents At Citi's Biopharma Back To School Conference Transcript

Cytokinetics, Incorporated (NASDAQ:CYTK) Citi's Biopharma Back to School Conference September 2, 2025 2:30 PM EDT Company Participants Robert I. Blum - CEO, President & Director Fady Malik - Executiv...

5 weeks ago - Seeking Alpha

Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential

MAPLE-HCM establishes Cytokinetics, Incorporated's aficamten as superior to metoprolol in obstructive HCM, reframing it as a potential first-line, best-in-class therapy. Commercial potential is signif...

5 weeks ago - Seeking Alpha

Cytokinetics, Incorporated - Exploring The Changing Treatment Paradigm Transcript

Cytokinetics, Incorporated -Exploring The Changing Treatment Paradigm Transcript Company Participants Diane Weiser - Senior Vice President of Corporate Affairs Fady Malik - Executive Vice President of...

5 weeks ago - Seeking Alpha

Cytokinetics Stock Jumps. The Biotech's Heart Drug Wows.

Trial results for aficamten were presented to cardiologists over the weekend. One analyst said the drug could be “best-in-class therapy.

5 weeks ago - Barrons

Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025

Additional Data from MAPLE-HCM Shows Aficamten  Improves Cardiac Structure and Function Compared to Metoprolol;  Simultaneous Publication in the Journal of the American College of Cardiology

5 weeks ago - GlobeNewsWire

Cytokinetics' drug more effective for heart disease symptoms than standard-of-care

Cytokinetics' experimental drug improved symptoms such as shortness of breath and chest pain better than a standard-of-care treatment in patients with a type of heart condition, detailed late-stage st...

5 weeks ago - Reuters

Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine

Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint Result Consistent Across All Prespecified Subgroups Company to Host Investor Event and...

5 weeks ago - GlobeNewsWire